PT2869841T - Novos regimes de reforço principal envolvendo polipétidos imunogénicos codificados por polinucleótidos - Google Patents

Novos regimes de reforço principal envolvendo polipétidos imunogénicos codificados por polinucleótidos

Info

Publication number
PT2869841T
PT2869841T PT137341111T PT13734111T PT2869841T PT 2869841 T PT2869841 T PT 2869841T PT 137341111 T PT137341111 T PT 137341111T PT 13734111 T PT13734111 T PT 13734111T PT 2869841 T PT2869841 T PT 2869841T
Authority
PT
Portugal
Prior art keywords
polynucleotides
polypeptides encoded
immunogenic polypeptides
regimens involving
boosting regimens
Prior art date
Application number
PT137341111T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2869841T publication Critical patent/PT2869841T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT137341111T 2012-07-05 2013-07-05 Novos regimes de reforço principal envolvendo polipétidos imunogénicos codificados por polinucleótidos PT2869841T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/063196 WO2014005643A1 (en) 2012-07-05 2012-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Publications (1)

Publication Number Publication Date
PT2869841T true PT2869841T (pt) 2021-10-28

Family

ID=48746554

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137341111T PT2869841T (pt) 2012-07-05 2013-07-05 Novos regimes de reforço principal envolvendo polipétidos imunogénicos codificados por polinucleótidos

Country Status (19)

Country Link
US (3) US20150209420A1 (instruction)
JP (1) JP6244358B2 (instruction)
KR (1) KR20150038010A (instruction)
CN (1) CN104780937A (instruction)
AU (1) AU2013285398A1 (instruction)
BR (1) BR112014033077A2 (instruction)
CA (1) CA2878367A1 (instruction)
DK (1) DK2869841T3 (instruction)
EA (1) EA201492230A1 (instruction)
ES (1) ES2895070T3 (instruction)
HU (1) HUE056675T2 (instruction)
IL (1) IL236414A0 (instruction)
IN (1) IN2014KN03063A (instruction)
LT (1) LT2869841T (instruction)
MX (1) MX365391B (instruction)
PT (1) PT2869841T (instruction)
SG (1) SG11201408746XA (instruction)
WO (2) WO2014005643A1 (instruction)
ZA (1) ZA201500102B (instruction)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
EP3154576A1 (en) * 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016036955A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
HRP20210113T1 (hr) 2016-04-05 2021-03-05 Janssen Vaccines & Prevention B.V. Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10517944B2 (en) * 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
AU2017272504A1 (en) 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
CA3076026A1 (en) * 2017-10-25 2019-05-02 Nouscom Ag Eukaryotic cell line
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511845B1 (en) * 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
ES2627288T3 (es) 2004-01-23 2017-07-27 Msd Italia S.R.L. Portadores de vacuna de adenovirus de chimpancé
EP2001516A4 (en) * 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008085502A2 (en) * 2007-01-05 2008-07-17 Inseron, Inc. A green fluorescent protein optimized for expression with self-cleaving polypeptides
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
US7863425B2 (en) * 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
KR101763093B1 (ko) * 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
KR20120096874A (ko) * 2009-05-18 2012-08-31 파나세아 바이오테크 리미티드 재조합 변형된 백시니아 앙카라 바이러스에 기반한 보편적 인플루엔자 백신
US9095546B2 (en) * 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
US9119813B2 (en) * 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV

Also Published As

Publication number Publication date
AU2013285398A1 (en) 2015-02-05
US20180256704A1 (en) 2018-09-13
MX2014016119A (es) 2015-09-23
BR112014033077A2 (pt) 2017-08-01
SG11201408746XA (en) 2015-01-29
ZA201500102B (en) 2017-09-27
JP2015526403A (ja) 2015-09-10
EA201492230A1 (ru) 2015-06-30
WO2014005643A1 (en) 2014-01-09
KR20150038010A (ko) 2015-04-08
CN104780937A (zh) 2015-07-15
IL236414A0 (en) 2015-02-26
WO2014006191A1 (en) 2014-01-09
HUE056675T2 (hu) 2022-02-28
CA2878367A1 (en) 2014-01-09
IN2014KN03063A (instruction) 2015-05-08
US20240091338A1 (en) 2024-03-21
MX365391B (es) 2019-05-31
US20150209420A1 (en) 2015-07-30
ES2895070T3 (es) 2022-02-17
JP6244358B2 (ja) 2017-12-06
DK2869841T3 (da) 2021-10-25
LT2869841T (lt) 2021-11-25

Similar Documents

Publication Publication Date Title
ZA201500102B (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
IL291571A (en) cx3cr1 binding polypeptides
EP2834259A4 (en) MODIFIED POLYNUCLEOTIDES
SG11201503741UA (en) Two-dimensional code
HUE061273T2 (hu) Immunogén készítmény
GB201220474D0 (en) Polypeptides
HUE040914T4 (hu) Immunogén készítmény
IL238079A0 (en) Immunogenic preparation
SG11201503742XA (en) Two-dimensional code
EP2848291A4 (en) GYRO
GB201223342D0 (en) Immunogenic composition
DK2941162T3 (en) Formeapparat til formet gulv
GB201218660D0 (en) Immunogenic composition
ZA201501562B (en) Treatment regimens
SI2869841T1 (sl) Novi režimi za ojačitev odziva, ki vključujejo imunogene polipeptide, ki jih kodirajo polinukleotidi
GB201210900D0 (en) Movable platforms
TWM433222U (en) Multifunctional hair-decoration swimming cap
GB201219944D0 (en) Water-powered motor
GB201213753D0 (en) Angle
GB201202102D0 (en) Indu-green energy bio-sustainable project
GB201213339D0 (en) Lev insided matt
GB201219337D0 (en) Garrods movement
AU347499S (en) Top
AU347497S (en) Top
AU347500S (en) Top